OKC pharma firm acquired in deal valued up to $665 million

If you are in a decision-making position in an Oklahoma company, is there any reason you wouldn’t want to consider doing business with a startup? You might think that there’s too much risk with a startup. Personally, I like optimism and passion. I favor businesses that stretch, that run lean, and that focus on cashflow. And I like to be part of helping a new business grow. I bet when you think about it, you do too.

If you are in a decision-making position in an Oklahoma company, is there any reason you wouldn’t want to consider doing business with a startup? You might think that there’s too much risk with a startup. Personally, I like optimism and passion. I favor businesses that stretch, that run lean, and that focus on cashflow. And I like to be part of helping a new business grow. I bet when you think about it, you do too.

By Scott Meacham Copyright © 2018, The Oklahoma Publishing Co. Anybody who’s ever heard me talk about building out Oklahoma’s innovation economy has heard me say that capital begets capital and deal flow begets dealRead more

Scott Rollins, CEO of Selexys Pharmaceuticals/Oklahoman photo provided by OCAST By Jim Stafford Copyright © 2017, The Oklahoma Publishing Co. Selexys Pharmaceuticals president and CEO Scott Rollins reflected on the lessons learned in the wakeRead more

A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.